Coya Therapeutics, Inc. issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3…
Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s co
How this was made
The 30-second read
Why it matters
The enrollment milestone suggests the trial is progressing on schedule, which may reduce execution risk and support the stock.
Market read
The news is a primary disclosure for a micro‑cap biotech, offering modest trading relevance.
What to watch
Potential regulatory delays or safety concerns could offset the positive enrollment news.
Background
Coya Therapeutics filed an 8‑K reporting the 100th patient enrollment in its ALSTARS trial for ALS, aiming for full enrollment of 120 patients.
Ticker impact
Company announced enrollment of the 100th patient in its Phase 2/3 ALS trial, indicating progress toward full enrollment.
Potential modest upside as the market prices in progress toward upcoming topline data.
Enrollment speed suggests trial is on track; however, actual efficacy data remains pending.
Market effects
Positive signal for the ALS biotech niche and may lift peer companies developing neurodegenerative therapies.
Limited to U.S. biotech investors; no broader regional effect.
Minor global impact, primarily of interest to specialty biotech funds.
Counterpoint
If trial enrollment stalls after this point, the early milestone could be overstated and lead to a sell‑off.
Key entities
- companyCoya Therapeutics, Inc.
Biotech firm developing COYA 302 for ALS.
